Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Stock Information for NCS Multistage Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NCS Multistage Holdings Inc.

Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.